Ligand Pharmaceuticals has expanded its global license and supply agreements with SAGE Therapeutics to also cover the use of Captisol in the development and commercialization of SAGE-689. Ligand received a licensing fee and will be eligible to receive potential milestones, royalties and revenue from Captisol material sales. SAGE will be responsible for all costs related to the program.   “This latest agreement represents an expansion of our existing relationship with SAGE and we are excited to...